Small Molecule Platform:
Kelun-Biotech's innovative small molecule drug R&D platform is supported by a world class team of domestic and foreign high-end talents. The platform includes a complete R&D functional system, covering the process including target validation, molecular design and screening, drugability evaluation, pharmaceutical development and clinical translation. Driven by advanced technologies, the platform integrates the advantages of classical medicinal chemistry design, computer-aided drug design (CADD) and virtual screening in an orderly manner. The platform focuses on targets with significant clinical value in the fields of oncology and autoimmunity. The platform has proven to effectively develops drugs with differentiated advantages, breakthroughs and innovations. The platform includes traditional small molecules and proteolysis-targeting chimeras (PROTACs). Since its establishment in 2014, the platform has independently completed the research and development of a number of innovative small molecule drugs, of which 8 projects have been approved to enter the clinical stage including 2 projects have entered the clinical phase II stage, and 1 project that has achieved overseas out-licensing. The R&D achievements of the platform have been widely recognized by international peers.